Following successful validation in the CHRYSALIS, CHRYSALIS-2, and PAPILLON clinical trials, amivantamab received FDA approval for treating metastatic NSCLC harboring EGFR exon 20 insertion mutations 48,49. Here, EGFR is linked to non-small cell lung carcinoma.